Bristol-Myers Squibb Company (BMY)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of 09:34 UTC · Figures derived from the full chain (824 contracts, 15 expirations) · IV own-history percentile appears after 60 recorded days (28 so far)
Expected move · Nov 20, 2026 (32 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±8.3% (range 55.16–65.21) by Nov 20, 2026. ATM straddle: 5.03 @ strike 60 · ATM IV: 33.8%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 54.17 | -10% | 84.2% | 15.8% |
| 57.18 | -5% | 67.8% | 32.2% |
| 60.19 | +0% | 48.0% | 52.0% |
| 63.20 | +5% | 29.5% | 70.5% |
| 66.21 | +10% | 15.8% | 84.2% |
Model-estimated probabilities of finishing above/below each level at expiration: estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Nov 20, 2026 · lognormal model with zero drift: an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Oct 23, 2026 | 4 | ±3.3% | 29.8% | 21.0K |
| Oct 30, 2026 | 11 | ±6.7% | 37.1% | 24.1K |
| Nov 06, 2026 | 18 | ±6.6% | 34.6% | 3,989 |
| Nov 13, 2026 | 25 | ±7.6% | 34.4% | 1,356 |
| Nov 20, 2026 | 32 | ±8.3% | 33.8% | 72.6K |
| Nov 27, 2026 | 39 | ±8.9% | 32.9% | 551 |
| Dec 18, 2026 | 60 | ±10.7% | 32.4% | 213.7K |
| Jan 15, 2027 | 88 | ±13.0% | 32.6% | 174.0K |
| Mar 19, 2027 | 151 | ±17.8% | 34.7% | 69.0K |
Open interest by strike · Nov 20
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 65 C · 43.5K80 C · 35.9K50 P · 34.0K60 P · 24.5K62.5 P · 23.8K
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Daily closes; Financial Modeling Prep.
Track record
Full history →Of 93 recorded snapshot-versus-outcome comparisons so far, the close landed inside the expected range 51.6% of the time.
Past earnings reactions
Avg |reaction| 4.1% · median 3.2% (20 reports). Two-session close-to-close window; definition
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offer
Healthcare · Drug Manufacturers - General · NYSE · Profile: Financial Modeling Prep
Related securities · Healthcare
MRNA · IV 109.7%UNH · IV 31.7%HIMS · IV 89.0%PFE · IV 26.0%LLY · IV 40.7%JNJ · IV 23.4%